SPOTLIGHT -
Dr Bhat is founder, president, and chief executive officer of
Reviva Pharmaceuticals Holdings Inc.
Open Label Phase 3 Study of Brilaroxazine for Schizophrenia Shows Efficacy, Tolerability
The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.